Osteoporosis in Parkinson's disease.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_7787EDEDDF11
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Osteoporosis in Parkinson's disease.
Périodique
Parkinsonism and Related Disorders
Auteur⸱e⸱s
Invernizzi M., Carda S., Viscontini G.S., Cisari C.
ISSN
1873-5126 (Electronic)
ISSN-L
1353-8020
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
15
Numéro
5
Pages
339-346
Langue
anglais
Notes
Publication types: Journal Article ; Review Publication Status: ppublish
Résumé
Patients affected by Parkinson's disease are at a high risk for fractures, mainly of the hip. These fractures are caused by falls due to postural imbalance, neurological impairment and reduced bone mass. The purpose of this study was (1) to investigate the correlations and the pathophysiological mechanisms underlying bone loss in Parkinson's disease and appraise bone loss or fracture risk reduction interventions; (2) to develop a research agenda that informs the design and development of risk reduction strategies. Osteoporosis and osteopenia are very common findings in patients with Parkinson's disease, affecting up to 91% of women and 61% of men. Reduced bone mass in Parkinsonian patients seems to be caused mainly by reduced mobility through a mechanism similar to that observed in other neurological diseases. Endocrine (such as vitamin D deficiency), nutritional and iatrogenic factors also play an important role in bone mass depletion. Female gender, disease duration and severity (Hoehn and Yahr stages III and IV), old age and low body mass index are related to more severe osteoporosis. Vitamin D supplementation and bisphosphonates seem to be effective in reducing the risk of nonvertebral fractures in patients affected by Parkinson's disease. Prevention and evaluation of osteoporosis through bone mass density assessment should be considered in all patients with Parkinson's disease.
Mots-clé
Aged, Body Mass Index, Bone Density/drug effects, Bone Density/physiology, Bone Diseases, Metabolic/epidemiology, Bone Diseases, Metabolic/etiology, Female, Fractures, Bone/epidemiology, Fractures, Bone/prevention & control, Human Growth Hormone/blood, Human Growth Hormone/therapeutic use, Humans, Male, Osteoporosis/epidemiology, Osteoporosis/etiology, Parkinson Disease/blood, Parkinson Disease/drug therapy, Sex Characteristics, Thyrotropin/therapeutic use, Vitamin D/therapeutic use
Pubmed
Création de la notice
25/03/2013 18:21
Dernière modification de la notice
15/07/2020 6:26
Données d'usage